{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"259"},{"groupId":"OG001","value":"360"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"384"}],"units":"Participants"}],"description":"Complete response is defined as a drop in PSA on protocol treatment to less than 0.2 ng/ml. Note that when the study opened many institutions could not detect PSA \\< 05 ng/ml.","groups":[{"description":"Radiation therapy (64.8 Gy) + placebo (daily 2 years)","id":"OG000","title":"Placebo"},{"description":"Radiation therapy (64.8 Gy) + bicalutamide (150 mg daily 2 years)","id":"OG001","title":"Bicalutamide"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible patients who did not withdraw consent.","reportingStatus":"POSTED","timeFrame":"End of protocol treatment, which is planned to last for two years","title":"PSA Complete Response at End of Protocol Treatment","type":"SECONDARY","unitOfMeasure":"Participants"}